← Back to Home

From Understanding Tumors to Influencing Treatment: 10x Genomics Plans Clinical Laboratory, Starting with Bladder Cancer

Single-cell and spatial biology have long excelled at mapping tumors, but they do not necessarily provide a direct answer to which drug a patient should receive. Through a CLIA laboratory expected to begin operations in 2027 and collaborations with hospitals, 10x Genomics is attempting to bridge the gap between research tools and clinical testing.

By SURL BioNews

Patients with the same type of cancer receiving the same treatment can still have vastly different responses. To explain these differences, researchers need to know not only which genes are active in a tumor, but also which types of cells the signals come from, where those cells are located within the tissue, and how they interact with the immune environment. 10x Genomics is now preparing to bring this high-resolution approach to clinical diagnostics. A key step is establishing its own CLIA-certified laboratory, which is expected to begin operations in 2027.

CLIA is the US regulatory framework governing the quality of laboratories that test human specimens. For 10x Genomics, whose core business consists of research instruments, reagents, and software, building its own laboratory means the company will no longer only supply platforms to researchers. It also aims to generate clinical evidence itself, establish testing workflows, and ultimately organize complex single-cell and spatial data into reports that physicians can use. The concept the company presented to investors early this year is to advance customer-led translational research alongside company-led diagnostic development.

One of the most concrete clinical settings for this approach is a multiyear bladder cancer study with Cleveland Clinic. The two parties will first analyze tumor specimens from patients with advanced disease who are receiving emerging therapies, combining Flex Apex single-cell transcriptomic analysis with Xenium spatial gene and protein expression data, with plans to expand to the Atera platform in the future. They will then link these molecular profiles to treatment outcomes to identify biomarkers that may predict responses to antibody-drug conjugates or immunotherapies.

The study is examining not only which targets are present on tumor cells, but also the cellular composition of the tumor microenvironment, the extent of immune-cell infiltration, and the spatial relationships among tumor, immune, and stromal cells. These clues may explain why a drug works in some patients but encounters intrinsic or acquired resistance in others. Only if reproducibly validated interpretation rules can be established will single-cell and spatial analysis have the potential to move beyond describing disease and become a tool for treatment selection.

The company’s planned oncology workflow uses Xenium to identify gene and protein expression within tissue, then adds whole-transcriptome single-cell data using Chromium Flex. It has also pursued cancer and autoimmune disease research with institutions including Dana-Farber and Brigham and Women's Hospital, indicating that its plans are not limited to bladder cancer but are intended to establish a clinical reporting framework that can be extended to different diseases.

However, establishing a CLIA-certified laboratory does not mean that a test has received regulatory approval, nor can it replace evidence of clinical utility. Publicly available information currently does not specify the number of participants in the bladder cancer study, its statistical design, validation cohort, testing time, or cost. Whether multimodal data can be reproduced consistently across hospitals, and whether the results genuinely improve treatment decisions, also remain to be answered by prospective studies. At this stage, the initiative is better characterized as building infrastructure for diagnostic development than as a mature product ready for clinical adoption.

References

  1. Genetic Engineering & Biotechnology News
  2. 10x Genomics, Inc. via PR Newswire
  3. 10x Genomics